Prolonged treatment of psychotic states. (Over 1600 patients treated continuously 3 to 7 years).
D000928:Antidepressive Agents / Q000627:therapeutic use; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008548:Melanosis / Q000139:chemically induced*; D001523:Mental Disorders / Q000188:drug therapy*; D010276:Parasympatholytics / Q000627:therapeutic use; D010640:Phenothiazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects* / Q000627:therapeutic use*
D000928:Antidepressive Agents; D010276:Parasympatholytics; D010640:Phenothiazines; D014149:Tranquilizing Agents; D002746:Chlorpromazine